2024 Annual Meeting | C31 - Sticker Shock—Drug Pricing and Your Patients

Date Sunday 04/14/24

Time 07:00 AM - 09:00 AM MDT Add To Calendar

Location Colorado Convention Center | 605

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Kavita Nair, PhD, FAAN

Topic(s) Practice, Policy, and Ethics

Learning Objectives The high cost of newer, innovative medications to treat neurologic disease has created both excitement and challenges for all stakeholders in the US health care systems. Payers solely determine which drugs to pay for, which patient populations will be covered, what level to offer coverage and what cost sharing patients face. All aspects of this decision making leave out of the patient's voice. However, for patient preferences to be given adequate consideration by decision makers they need to be quantified. Through presentations from experts in patient preferences research, neurologists who have overcome access barriers by payers and those working with rare disease populations where patient preferences could differ from payer choices, faculty will facilitate an understanding of value assessment from the patient perspective for high cost drugs.

CME Available 2.00 CME credits

Core Competencies Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:25 AM MDT	Speaker	The PAVE (Patient-driven Values in Healthcare Evaluation) Center Model for Assessing Patient Preferences Julia Slejko
07:25 AM - 07:50 AM MDT	Speaker	The Cost to Latino Patients: High Cost Specialty Drugs in NMOSD Rebecca Romero, MD, FAAN
07:50 AM - 08:15 AM MDT	Speaker	Busting Barriers for Patients: The Neurologists Magic Tricks Rosemarie E. Walch, DO
08:15 AM - 08:40 AM MDT	Speaker	The Value Proposition of High Cost Drugs Kavita Nair, PhD, FAAN
08:15 AM - 09:15 AM MDT	Discussion	Panel Discussion Kavita Nair, PhD, FAAN, Rebecca Romero, MD, FAAN, Rosemarie E. Walch, DO, Julia Slejko

Faculty Disclosures
Kavita Nair, PhD, FAAN	Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Healthcare. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS.
Rebecca Romero, MD, FAAN	Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics . Dr. Romero has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Romero has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon.
Rosemarie E. Walch, DO	Dr. Walch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech/Roche. Dr. Walch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb . Dr. Walch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Walch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Walch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Walch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Walch has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Walch has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. Dr. Walch has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Walch has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Walch has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Walch has received research support from Genentech/Roche. The institution of Dr. Walch has received research support from Sanofi. The institution of Dr. Walch has received research support from EMD Serono. Dr. Walch has received research support from TG Therapeutics . The institution of Dr. Walch has received research support from Novartis. The institution of Dr. Walch has received research support from Alexion. The institution of Dr. Walch has received research support from Amgen .
Julia Slejko	No disclosure on file